Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

Immunity

Volumn 44, Issue 4, 2016, Pages 924-938

  Salmon, Hélène ^a   Idoyaga, Juliana ^b   Rahman, Adeeb ^a   Leboeuf, Marylène ^a   Remark, Romain ^a   Jordan, Stefan ^a   Casanova Acebes, Maria ^a   Khudoynazarova, Makhzuna ^a   Agudo, Judith ^a   Tung, Navpreet ^a   Chakarov, Svetoslav ^f   Rivera, Christina ^a   Hogstad, Brandon ^a   Bosenberg, Marcus ^c   Hashimoto, Daigo ^d   Gnjatic, Sacha ^a   Bhardwaj, Nina ^a   Palucka, Anna Karolina ^e   Brown, Brian D ^a   Brody, Joshua ^a   Ginhoux, Florent ^f   Merad, Miriam ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e JACKSON LABORATORY   (United States)

^f AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD103 ANTIGEN; GAMMA INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; ALPHA E INTEGRINS; ALPHA INTEGRIN; BRAF PROTEIN, MOUSE; CD135 ANTIGEN; CD274 PROTEIN, MOUSE; FLT3 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; LYMPH NODE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN PRESENTATION; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOLOGY; EXPERIMENTAL MELANOMA; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FMS-LIKE TYROSINE KINASE 3; INTEGRIN ALPHA CHAINS; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MICE, KNOCKOUT; POLY I-C; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84964344569     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.03.012     Document Type: Article

References (45)

1. Bogunovic D., O'Neill D.W., Belitskaya-Levy I., Vacic V., Yu Y.L., Adams S., Darvishian F., Berman R., Shapiro R., Pavlick A.C., et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. USA 2009, 106:20429-20434.
2. Bogunovic D., Manches O., Godefroy E., Yewdall A., Gallois A., Salazar A.M., Marie I., Levy D.E., Bhardwaj N. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 2011, 71:5467-5476.
3. Broz M.L., Binnewies M., Boldajipour B., Nelson A.E., Pollack J.L., Erle D.J., Barczak A., Rosenblum M.D., Daud A., Barber D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014, 26:638-652.
4. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
5. Cooper Z.A., Juneja V.R., Sage P.T., Frederick D.T., Piris A., Mitra D., Lo J.A., Hodi F.S., Freeman G.J., Bosenberg M.W., et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2014, 2:643-654.
6. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.A., Ventre E., Vu Manh T.P., Baranek T., Storset A.K., Marvel J., et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1283-1292.
7. Damsky W.E., Curley D.P., Santhanakrishnan M., Rosenbaum L.E., Platt J.T., Gould Rothberg B.E., Taketo M.M., Dankort D., Rimm D.L., McMahon M., Bosenberg M. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20:741-754.
8. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., Azuma M., Krummel M.F., Bluestone J.A. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009, 10:1185-1192.
9. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
10. Förster R., Schubel A., Breitfeld D., Kremmer E., Renner-Müller I., Wolf E., Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
11. Frei E., Holland J.F., Schneiderman M.A., Pinkel D., Selkirk G., Freireich E.J., Silver R.T., Gold G.L., Regelson W. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 1958, 13:1126-1148.
12. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 2011, 208:2005-2016.
13. Gajewski T.F., Woo S.R., Zha Y., Spaapen R., Zheng Y., Corrales L., Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:268-276.
14. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
15. Ginhoux F., Liu K., Helft J., Bogunovic M., Greter M., Hashimoto D., Price J., Yin N., Bromberg J., Lira S.A., et al. The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 2009, 206:3115-3130.
16. Guilliams M., Ginhoux F., Jakubzick C., Naik S.H., Onai N., Schraml B.U., Segura E., Tussiwand R., Yona S. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 2014, 14:571-578.
17. Hashimoto D., Miller J., Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011, 35:323-335.
18. Helft J., Manicassamy B., Guermonprez P., Hashimoto D., Silvin A., Agudo J., Brown B.D., Schmolke M., Miller J.C., Leboeuf M., et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Invest. 2012, 122:4037-4047.
19. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
20. Hermans I.F., Silk J.D., Yang J., Palmowski M.J., Gileadi U., McCarthy C., Salio M., Ronchese F., Cerundolo V. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 2004, 285:25-40.
21. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., Calderon B., Schraml B.U., Unanue E.R., Diamond M.S., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008, 322:1097-1100.
22. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., Chen C.J., Dunbar P.R., Wadley R.B., Jeet V., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010, 207:1247-1260.
23. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
24. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
25. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
26. Liu K., Nussenzweig M.C. Origin and development of dendritic cells. Immunol. Rev. 2010, 234:45-54.
27. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., Salazar A.M., Colonna M., Steinman R.M. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206:1589-1602.
28. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv. Drug Deliv. Rev. 2008, 60:805-812.
29. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., Melief C.J., Ildstad S.T., Kast W.M., Deleo A.B., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995, 1:1297-1302.
30. Merad M., Sathe P., Helft J., Miller J., Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 2013, 31:563-604.
31. Miller J.C., Brown B.D., Shay T., Gautier E.L., Jojic V., Cohain A., Pandey G., Leboeuf M., Elpek K.G., Helft J., et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 2012, 13:888-899. Immunological Genome Consortium.
32. Murphy T.L., Tussiwand R., Murphy K.M. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 2013, 13:499-509.
33. Page D.B., Postow M.A., Callahan M.K., Allison J.P., Wolchok J.D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014, 65:185-202.
34. Poulin L.F., Salio M., Griessinger E., Anjos-Afonso F., Craciun L., Chen J.L., Keller A.M., Joffre O., Zelenay S., Nye E., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J. Exp. Med. 2010, 207:1261-1271.
35. Salmon H., Franciszkiewicz K., Damotte D., Dieu-Nosjean M.C., Validire P., Trautmann A., Mami-Chouaib F., Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 2012, 122:899-910.
36. Sathe P., Pooley J., Vremec D., Mintern J., Jin J.O., Wu L., Kwak J.Y., Villadangos J.A., Shortman K. The acquisition of antigen cross-presentation function by newly formed dendritic cells. J. Immunol. 2011, 186:5184-5192.
37. Savina A., Jancic C., Hugues S., Guermonprez P., Vargas P., Moura I.C., Lennon-Duménil A.M., Seabra M.C., Raposo G., Amigorena S. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006, 126:205-218.
38. Schlitzer A., Sivakamasundari V., Chen J., Sumatoh H.R., Schreuder J., Lum J., Malleret B., Zhang S., Larbi A., Zolezzi F., et al. Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat. Immunol. 2015, 16:718-728.
39. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
40. Sharma P., Allison J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015, 161:205-214.
41. Sluijter B.J., van den Hout M.F., Koster B.D., van Leeuwen P.A., Schneiders F.L., van de Ven R., Molenkamp B.G., Vosslamber S., Verweij C.L., van den Tol M.P., et al. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation. Cancer Immunol. Res. 2015, 3:495-505.
42. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2014, 2:3.
43. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
44. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
45. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 2012, 209:1201-1217.